- slider1.jpg
- slider1.jpg
- slider1.jpg
- slider1.jpg
- slider1.jpg
TREATING DEADLY INFLAMMATION
CytoSorb® is a unique blood purification therapy to control deadly inflammation in life-threatening illnesses in the ICU and cardiac surgery. The product is currently approved in the European Union and distributed in 58 countries around the world.
THE POWER OF THE BEAD
Powered by massive surface area, our purification technologies are based on biocompatible, highly porous polymer beads that can actively remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption.
INFORMATION FOR INVESTORS
CytoSorbents is a leader in critical care immunotherapy. The company is committed to serving the best interests of our patients and their families, our customers, our employees, and our shareholders.
Recent News
- CytoSorbents Highlights CytoSorb Use in Sepsis Patients During Sepsis Awareness Month and World Sepsis Day 2020
- CytoSorbents Announces the "CytoSorb Therapy in COVID-19 ICU Patients" (CTC) Registry Is Actively Enrolling
- Terumo Cardiovascular and CytoSorbents Collaborate to Commercialize CytoSorb® in Ten U.S. Hotspot States under Emergency Use Authorization for COVID-19
- CytoSorbents Partners with InvoSurg and Surgical Partners to Commercialize CytoSorb® in the U.S. Northeast, Mid-Atlantic, and Florida under FDA Emergency Use Authorization for COVID-19
- CytoSorbents Reports Record Second Quarter 2020 Financial Results
- slider1.jpg
CytoSorbents is a leader in critical care immunotherapy. The company is committed to serving the best interests of our patients and their families, our customers, our employees, and our shareholders.
CytoSorb® is a unique blood purification therapy.The product is currently approved in the European Union and distributed in 58 countries around the world